Citations (100)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Fahui Li, Lihui Zhang, Jinhong Feng & Lei Zhang. (2022) Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 2017-2035.
Read now
Read now
Larysa Strilchuk, Giuliano Tocci, Federica Fogacci & Arrigo F. G. Cicero. (2020) An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opinion on Pharmacotherapy 21:5, pages 531-539.
Read now
Read now
Lingling Zhang, Kangping Song, Mengting Zhu, Jinling Shi, Huijuan Zhang, Liang Xu & Yingzhu Chen. (2016) Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. International Journal of Neuroscience 126:8, pages 675-680.
Read now
Read now
Anke Loregger, Emma Claire Laura Cook, Jessica Kristin Nelson, Martina Moeton, Laura Jane Sharpe, Susanna Engberg, Madina Karimova, Gilles Lambert, Andrew John Brown & Noam Zelcer. (2016) A MARCH6 and IDOL E3 Ubiquitin Ligase Circuit Uncouples Cholesterol Synthesis from Lipoprotein Uptake in Hepatocytes. Molecular and Cellular Biology 36:2, pages 285-294.
Read now
Read now
Michel Farnier. (2015) An evaluation of alirocumab for the treatment of hypercholesterolemia. Expert Review of Cardiovascular Therapy 13:12, pages 1307-1323.
Read now
Read now
Christopher J Duff & Nigel M Hooper. (2011) PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opinion on Therapeutic Targets 15:2, pages 157-168.
Read now
Read now
Marianne Abifadel, Jihane Pakradouni, Matthieu Collin, Marie-Elisabeth Samson-Bouma, Mathilde Varret, Jean-Pierre Rabès & Catherine Boileau. (2010) Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opinion on Therapeutic Patents 20:11, pages 1547-1571.
Read now
Read now
Articles from other publishers (93)
Gabriela Alexandra Solano Peña, Gabriela Fernanda Acurio Armas, Gabriela Alejandra Díaz Teran, Susana Patricia Palacios Serrano, Andrea Carolina Cobo Reyes, Daniel Albino Pullas Taboada & Gissel Katherine Carvajal Chango. (2023) Inhibición de PCSK9: una nueva alternativa para reducir el colesterol y prevenir la enfermedad cardiovascular aterosclerosa. Salud, Ciencia y Tecnología 3, pages 587.
Crossref
Crossref
Ziqing Wang & Jian Li. (2023) Lipoprotein(a) in patients with breast cancer after chemotherapy: exploring potential strategies for cardioprotection. Lipids in Health and Disease 22:1.
Crossref
Crossref
Thobile Ngqaneka, Kenechukwu Obikeze, Zandisiwe E. Magwebu & Chesa G. Chauke. (2022)
Proprotein convertase subtilisin/kexin type 9 genetic screening using the vervet (
Chlorocebus aethiops
) model
. Journal of Medical Primatology 52:1, pages 45-52.
Crossref
Crossref
Charalampos Loutradis, Pantelis A. Sarafidis, Alberto Ortiz & Charles J. Ferro. (2022) Is Our Increasing Understanding of PCSK9 and Lp(a) Metabolism the Key to Unlocking the Paradox of Statins Ineffectiveness in Reducing Cardiovascular Events in Advanced CKD?. SN Comprehensive Clinical Medicine 4:1.
Crossref
Crossref
Runli Liang, Yingnan Zhang, Guangzhong Ma & Shaopeng Wang. (2022) Charge-Sensitive Optical Detection of Binding Kinetics between Phage-Displayed Peptide Ligands and Protein Targets. Biosensors 12:6, pages 394.
Crossref
Crossref
Aureli Luquero, Gemma Vilahur, Laura Casani, Lina Badimon & Maria Borrell‐Pages. (2022) Differential cholesterol uptake in liver cells: A role for PCSK9. The FASEB Journal 36:5.
Crossref
Crossref
Meidi Utami Puteri, Nuriza Ulul Azmi, Mitsuyasu Kato & Fadlina Chany Saputri. (2022) PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction. Life 12:2, pages 190.
Crossref
Crossref
Masato Hamasaki, Naoki Sakane, Kazuo Hara & Kazuhiko Kotani. (2021) LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy. Journal of Clinical Laboratory Analysis 35:11.
Crossref
Crossref
Khadijeh Mahboobnia, Matteo Pirro, Ettore Marini, Francesco Grignani, Evgeny E. Bezsonov, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2021) PCSK9 and cancer: Rethinking the link. Biomedicine & Pharmacotherapy 140, pages 111758.
Crossref
Crossref
D Matías-Pérez, AD Pérez-Santiago, MA Sánchez Medina, JJ Alpuche Osorno & IA García-Montalvo. (2021)
PCSK9
gene participates in the development of primary dyslipidemias
. Balkan Journal of Medical Genetics 24:1, pages 5-14.
Crossref
Crossref
Jin-Taek Hwang, Eunji Choi, Hyo-Kyoung Choi, Jae-Ho Park & Min-Yu Chung. (2021) The Cholesterol-Lowering Effect of Capsella Bursa-Pastoris Is Mediated via SREBP2 and HNF-1α-Regulated PCSK9 Inhibition in Obese Mice and HepG2 Cells. Foods 10:2, pages 408.
Crossref
Crossref
Mateusz Maligłówka, Łukasz Bułdak, Bogusław Okopień & Aleksandra Bołdys. (2021)
Skutki hamowania funkcji PCSK9 w obrębie wybranych tkanek
*
. Postępy Higieny i Medycyny Doświadczalnej 75:1, pages 385-397.
Crossref
Crossref
Hui-xian Yang, Min Zhang, Shi-yin Long, Qin-hui Tuo, Ying Tian, Jian-xiong Chen, Cai-ping Zhang & Duan-fang Liao. (2020) Cholesterol in LDL receptor recycling and degradation. Clinica Chimica Acta 500, pages 81-86.
Crossref
Crossref
Carmen Lammi, Jacopo Sgrignani, Anna Arnoldi, Giordano Lesma, Claudia Spatti, Alessandra Silvani & Giovanni Grazioso. (2019) Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors. Journal of Medicinal Chemistry 62:13, pages 6163-6174.
Crossref
Crossref
Gang Wang, Zhenbin Liu, Menghu Li, Yu Li, Sahir Sultan Alvi, Irfan Ahmad Ansari & M. Salman Khan. (2019) Ginkgolide B Mediated Alleviation of Inflammatory Cascades and Altered Lipid Metabolism in HUVECs via Targeting PCSK-9 Expression and Functionality. BioMed Research International 2019, pages 1-12.
Crossref
Crossref
Keshav Kumar Gupta, Shair Ali & Ranjodh Singh Sanghera. (2018) Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. Cardiology and Therapy 8:1, pages 5-20.
Crossref
Crossref
Shijie Cao, Peixiang Xu, Jiankun Yan, Hui Liu, Lu Liu, Lina Cheng, Feng Qiu & Ning Kang. (2018) Berberrubine and its analog, hydroxypropyl‐berberrubine, regulate LDLR and PCSK9 expression via the ERK signal pathway to exert cholesterol‐lowering effects in human hepatoma HepG2 cells. Journal of Cellular Biochemistry 120:2, pages 1340-1349.
Crossref
Crossref
Shengtao Xu, Shanshan Luo, Zheying Zhu & Jinyi Xu. (2019) Small molecules as inhibitors of PCSK9: Current status and future challenges. European Journal of Medicinal Chemistry 162, pages 212-233.
Crossref
Crossref
Satish K. Singh, Hanns-Christian Mahler, Christine Hartman & Craig A. Stark. (2018) Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants?. Journal of Pharmaceutical Sciences 107:11, pages 2735-2741.
Crossref
Crossref
Jaru Taechalertpaisarn, Bosheng Zhao, Xiaowen Liang & Kevin Burgess. (2018) Small Molecule Inhibitors of the PCSK9·LDLR Interaction. Journal of the American Chemical Society 140:9, pages 3242-3249.
Crossref
Crossref
Hong Wan, Barry Gumbiner, Tenshang Joh, Tom Riel, Chandrasekhar Udata, Philippe Forgues & Pamela D. Garzone. (2017) Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects. Clinical Therapeutics 39:11, pages 2243-2259.e5.
Crossref
Crossref
Lili Gu, Yue Wang, Yaqiong Xu, Qinghua Tian, Gaoxin Lei, Cheng Zhao, Zhan Gao, Qin Pan, Wenfeng Zhao, Liu Nong & Shuhua Tan. (2017)
Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression
in vitro
and
in vivo
. Oncotarget 8:46, pages 80826-80840.
Crossref
Crossref
Lu-Shan Liu, Xue-Qin Bai, Ya Gao, Qi Wu, Zhong Ren, Qing Li, Li-Hong Pan, Ni-Ya He, Juan Peng & Zhi-Han Tang. (2017) PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway. Journal of Alzheimer's Disease 57:3, pages 723-734.
Crossref
Crossref
. (2017) 家族性高コレステロール血症に対するPCSK9阻害剤の効果. Journal of JCS Cardiologists 25:2, pages 145-149.
Crossref
Crossref
Hyo-Kyoung Choi, Jin-Taek Hwang, Tae-Gyu Nam, Sung Hee Kim, Dong-Kook Min, Sahng Wook Park & Min-Yu Chung. (2017) Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells. Food & Function 8:12, pages 4582-4591.
Crossref
Crossref
Rui-xia Xu, Na-qiong Wu, Sha Li, Yan Zhang, Xiao-lin Li, Yuan-lin Guo, Cheng-gang Zhu, Geng Liu, Qian Dong & Jian-jun Li. (2015) Effects of Hedan Tablet (荷丹片) on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study. Chinese Journal of Integrative Medicine 22:9, pages 660-665.
Crossref
Crossref
Elodie Weider, Delia Susan-Resiga, Rachid Essalmani, Josée Hamelin, Marie-Claude Asselin, Surendra Nimesh, Yahya Ashraf, Keith L. Wycoff, Jianbing Zhang, Annik Prat & Nabil G. Seidah. (2016) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. Journal of Biological Chemistry 291:32, pages 16659-16671.
Crossref
Crossref
Jessica Kristine NelsonVincenzo SorrentinoRossella Avagliano TrezzaClaire HerideSylvie UrbeBen DistelNoam Zelcer. (2016) The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL. Circulation Research 118:3, pages 410-419.
Crossref
Crossref
Dong An, Xiaowei Wei, Hui Li, Hui Gu, Tianchu Huang, Guifeng Zhao, Bo Liu, Weilin Wang, Lizhu Chen, Wei Ma, Henan Zhang, Songying Cao & Zhengwei Yuan. (2015) Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. Scientific Reports 5:1.
Crossref
Crossref
Rui-Xia Xu, Jun Liu, Xiao-Lin Li, Sha Li, Yan Zhang, Yan-Jun Jia, Jing Sun & Jian-Jun Li. (2015) Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms. Journal of Translational Medicine 13:1.
Crossref
Crossref
A. Sahebkar, L. E. Simental-Mendía, F. Guerrero-Romero, J. Golledge & G. F. Watts. (2015) Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Diabetes, Obesity and Metabolism 17:11, pages 1042-1055.
Crossref
Crossref
Nathalie BergeronBinh An P. PhanYunchen DingAleyna FongRonald M. Krauss. (2015) Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. Circulation 132:17, pages 1648-1666.
Crossref
Crossref
Lee Joseph & Jennifer G. Robinson. (2015) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Progress in Cardiovascular Diseases 58:1, pages 19-31.
Crossref
Crossref
Robert P. Giugliano & Marc S. Sabatine. (2015) Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. Journal of the American College of Cardiology 65:24, pages 2638-2651.
Crossref
Crossref
Cristina S.J. Rocha, Oscar P.B. Wiklander, Lilian Larsson, Pedro M.D. Moreno, Paolo Parini, Karin E. Lundin & C.I. Edvard Smith. (2015) RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form. Journal of Molecular and Cellular Cardiology 82, pages 186-193.
Crossref
Crossref
Wen Guo, Jinxiang Fu, Xiaoli Chen, Beibei Gao, Zhenzhen Fu, Hongqi Fan, Qin Cui, Xiaohui Zhu, Yang Zhao, Tao Yang, Daping Fan & Hongwen Zhou. (2015) The Effects of Estrogen on Serum Level and Hepatocyte Expression of PCSK9. Metabolism 64:4, pages 554-560.
Crossref
Crossref
Bin Dong, Amar Bahadur Singh, Salman Azhar, Nabil G. Seidah & Jingwen Liu. (2015) High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels. Atherosclerosis 239:2, pages 364-374.
Crossref
Crossref
Na-Qiong Wu, Sha Li & Jian-Jun Li. (2015) Update of Clinical Trials of Anti-PCSK9 Antibodies. Cardiovascular Drugs and Therapy 29:2, pages 159-169.
Crossref
Crossref
Catherine E. de Keyser, Matthijs L. Becker, Albert Hofman, Jan J. Lous, André G. Uitterlinden, Loes E. Visser & Bruno H. Stricker. (2015) The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levels. Pharmacogenetics and Genomics 25:3, pages 134-142.
Crossref
Crossref
Rasha H. Alghamdi, Paul O'Reilly, Chunyu Lu, James Gomes, Thomas A. Lagace & Ajoy Basak. (2015) LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153–421): Design, synthesis and biochemical evaluation. European Journal of Medicinal Chemistry 92, pages 890-907.
Crossref
Crossref
Bin Dong, Hai Li, Amar Bahadur Singh, Aiqin Cao & Jingwen Liu. (2015) Inhibition of PCSK9 Transcription by Berberine Involves Down-regulation of Hepatic HNF1α Protein Expression through the Ubiquitin-Proteasome Degradation Pathway. Journal of Biological Chemistry 290:7, pages 4047-4058.
Crossref
Crossref
Michel Farnier. 2015. Combination Therapy In Dyslipidemia. Combination Therapy In Dyslipidemia
99
117
.
Rui-Xia Xu, Sha Li, Yan Zhang, Xiao-Lin Li, Yuan-Lin Guo, Cheng-Gang Zhu & Jian-Jun Li. (2014) Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids in Health and Disease 13:1.
Crossref
Crossref
Zuhier Awan, Alexis Baass & Jacques Genest. (2014) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): Lessons Learned from Patients with Hypercholesterolemia. Clinical Chemistry 60:11, pages 1380-1389.
Crossref
Crossref
Bin Dong, Amar Bahadur Singh, Chin Fung, Kelvin Kan & Jingwen Liu. (2014) CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis 235:2, pages 449-462.
Crossref
Crossref
Kévin Ly, Yascara Grisel Luna Saavedra, Maryssa Canuel, Sophie Routhier, Roxane Desjardins, Josée Hamelin, Janice Mayne, Claude Lazure, Nabil G. Seidah & Robert Day. (2014) Annexin A2 Reduces PCSK9 Protein Levels via a Translational Mechanism and Interacts with the M1 and M2 Domains of PCSK9. Journal of Biological Chemistry 289:25, pages 17732-17746.
Crossref
Crossref
Nabil G. SeidahZuhier AwanMichel ChrétienMajambu Mbikay. (2014) PCSK9. Circulation Research 114:6, pages 1022-1036.
Crossref
Crossref
QI WU, ZHI-HAN TANG, JUAN PENG, LING LIAO, LI-HONG PAN, CHUN-YAN WU, ZHI-SHENG JIANG, GUI-XUE WANG & LU-SHAN LIU. (2014) The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer’s disease progression (Review). Biomedical Reports 2:2, pages 167-171.
Crossref
Crossref
Caroline RichardPatrick CoutureEsther M.M. OoiAndré J. TremblaySophie DesrochesAmélie CharestAlice H. LichtensteinBenoît Lamarche. (2014)
Effect of Mediterranean Diet With and Without Weight Loss on Apolipoprotein B
100
Metabolism in Men With Metabolic Syndrome
. Arteriosclerosis, Thrombosis, and Vascular Biology 34:2, pages 433-438.
Crossref
Crossref
Nabil A. Elshourbagy, Harold V. Meyers & Sherin S. Abdel-Meguid. (2014) Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia. Medical Principles and Practice 23:2, pages 99-111.
Crossref
Crossref
Yingnan Zhang, Charles Eigenbrot, Lijuan Zhou, Steven Shia, Wei Li, Clifford Quan, Jeffrey Tom, Paul Moran, Paola Di Lello, Nicholas J. Skelton, Monica Kong-Beltran, Andrew Peterson & Daniel Kirchhofer. (2014) Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor. Journal of Biological Chemistry 289:2, pages 942-955.
Crossref
Crossref
Michel Farnier. (2014) PCSK9: From discovery to therapeutic applications. Archives of Cardiovascular Diseases 107:1, pages 58-66.
Crossref
Crossref
Majambu Mbikay, Janice Mayne & Michel Chrétien. (2013) Proprotein Convertases Subtilisin/Kexin Type 9, an enzyme turned escort protein: Hepatic and extra hepatic functions (第9型前蛋白转换酶-枯草溶菌素/蛋白酶K，一种酶转变的护送蛋白：在肝脏与肝外的功能). Journal of Diabetes 5:4, pages 391-405.
Crossref
Crossref
V. Conway, P. Couture, C. Richard, S.F. Gauthier, Y. Pouliot & B. Lamarche. (2013) Impact of buttermilk consumption on plasma lipids and surrogate markers of cholesterol homeostasis in men and women. Nutrition, Metabolism and Cardiovascular Diseases 23:12, pages 1255-1262.
Crossref
Crossref
Michel Farnier. (2013) PCSK9 inhibitors. Current Opinion in Lipidology 24:3, pages 251-258.
Crossref
Crossref
Maryssa Canuel, Xiaowei Sun, Marie-Claude Asselin, Eustache Paramithiotis, Annik Prat & Nabil G. Seidah. (2013) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1). PLoS ONE 8:5, pages e64145.
Crossref
Crossref
Li Shen, Hong-chun Peng, Shannon N. Nees, Shui-ping Zhao & Dan-yan Xu. (2013) Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport. FEBS Letters 587:9, pages 1271-1274.
Crossref
Crossref
A.L. Catapano & N. Papadopoulos. (2013) The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 228:1, pages 18-28.
Crossref
Crossref
Heiner K. Berthold, Nabil G. Seidah, Suzanne Benjannet & Ioanna Gouni-Berthold. (2013) Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels. PLoS ONE 8:3, pages e60095.
Crossref
Crossref
Tanja Kosenko, Mia Golder, Geoffrey Leblond, Willy Weng & Thomas A. Lagace. (2013) Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation. Journal of Biological Chemistry 288:12, pages 8279-8288.
Crossref
Crossref
C. Stefanutti & U. Julius. (2013) Lipoprotein apheresis: State of the art and novelties. Atherosclerosis Supplements 14:1, pages 19-27.
Crossref
Crossref
Nabil G. Seidah. 2013. Handbook of Biologically Active Peptides. Handbook of Biologically Active Peptides
1821
1828
.
Nabil G. Seidah. 2013. Handbook of Proteolytic Enzymes. Handbook of Proteolytic Enzymes
3315
3322
.
Michel Chrétien. (2012) My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. Biochemistry and Cell Biology 90:6, pages 750-768.
Crossref
Crossref
Yascara Grisel Luna Saavedra, Robert Day & Nabil G. Seidah. (2012) The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway. Journal of Biological Chemistry 287:52, pages 43492-43501.
Crossref
Crossref
Michael T. Lipari, Wei Li, Paul Moran, Monica Kong-Beltran, Tao Sai, Joyce Lai, S. Jack Lin, Ganesh Kolumam, Jose Zavala-Solorio, Anita Izrael-Tomasevic, David Arnott, Jianyong Wang, Andrew S. Peterson & Daniel Kirchhofer. (2012) Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels. Journal of Biological Chemistry 287:52, pages 43482-43491.
Crossref
Crossref
Suzanne Benjannet, Josée Hamelin, Michel Chrétien & Nabil G. Seidah. (2012) Loss- and Gain-of-function PCSK9 Variants. Journal of Biological Chemistry 287:40, pages 33745-33755.
Crossref
Crossref
Elena Fattori, Manuela Cappelletti, Paola Lo Surdo, Alessandra Calzetta, Claus Bendtsen, Yan G. Ni, Shilpa Pandit, Ayesha Sitlani, Giuseppe Mesiti, Andrea Carfí & Paolo Monaci. (2012) Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice. Journal of Lipid Research 53:8, pages 1654-1661.
Crossref
Crossref
Nabil G. Seidah, Steve Poirier, Maxime Denis, Rex Parker, Bowman Miao, Claudio Mapelli, Annik Prat, Hanny Wassef, Jean Davignon, Katherine A. Hajjar & Gaétan Mayer. (2012) Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation. PLoS ONE 7:7, pages e41865.
Crossref
Crossref
Hai LiJingwen Liu. (2012)
The novel function of HINFP as a co-activator in sterol-regulated transcription of
PCSK9
in HepG2 cells
. Biochemical Journal 443:3, pages 757-768.
Crossref
Crossref
Nabil G. Seidah & Annik Prat. (2012) The biology and therapeutic targeting of the proprotein convertases. Nature Reviews Drug Discovery 11:5, pages 367-383.
Crossref
Crossref
Lin-Zhang Huang & Hai-Bo Zhu. (2012) Novel LDL-oriented pharmacotherapeutical strategies. Pharmacological Research 65:4, pages 402-410.
Crossref
Crossref
Caroline Richard, Patrick Couture, Sophie Desroches, Suzanne Benjannet, Nabil G. Seidah, Alice H. Lichtenstein & Benoît Lamarche. (2011) Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome. British Journal of Nutrition 107:5, pages 705-711.
Crossref
Crossref
Maxime DenisJadwiga MarcinkiewiczAhmed ZaidDany GauthierSteve PoirierClaude LazureNabil G. SeidahAnnik Prat. (2012) Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice. Circulation 125:7, pages 894-901.
Crossref
Crossref
Zuhier Awan, Nabil G Seidah, Jean G MacFadyen, Suzanne Benjannet, Daniel I Chasman, Paul M Ridker & Jacques Genest. (2012) Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial. Clinical Chemistry 58:1, pages 183-189.
Crossref
Crossref
Fen Du, Yvonne Hui, Michelle Zhang, MacRae F. Linton, Sergio Fazio & Daping Fan. (2011) Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein. Journal of Biological Chemistry 286:50, pages 43054-43061.
Crossref
Crossref
Estelle Rousselet, Jadwiga Marcinkiewicz, Jasna Kriz, Ann Zhou, Mary E. Hatten, Annik Prat & Nabil G. Seidah. (2011) PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. Journal of Lipid Research 52:7, pages 1383-1391.
Crossref
Crossref
Michel Farnier. (2011) The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Hyperlipidemia. American Journal Cardiovascular Drugs 11:3, pages 145-152.
Crossref
Crossref
André J. Tremblay, Benoît Lamarche, Valéry Lemelin, Lizbeth Hoos, Suzanne Benjannet, Nabil G. Seidah, Jr. Harry R. Davis & Patrick Couture. (2011) Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. Journal of Lipid Research 52:3, pages 558-565.
Crossref
Crossref
Aiqin Cao, Minhao Wu, Hai Li & Jingwen Liu. (2011) Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. Journal of Lipid Research 52:3, pages 518-530.
Crossref
Crossref
Nabil G. Seidah. (2011) What lies ahead for the proprotein convertases?. Annals of the New York Academy of Sciences 1220:1, pages 149-161.
Crossref
Crossref
Akl C Fahed & Georges M Nemer. (2011) Familial Hypercholesterolemia: The Lipids or the Genes?. Nutrition & Metabolism 8:1, pages 23.
Crossref
Crossref
Robert J Konrad, Jason S Troutt & Guoqing Cao. (2011) Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids in Health and Disease 10:1, pages 38.
Crossref
Crossref
Suzanne Benjannet, Yascara Grisel Luna Saavedra, Josée Hamelin, Marie-Claude Asselin, Rachid Essalmani, Antonella Pasquato, Peter Lemaire, Gerald Duke, Bowman Miao, Franck Duclos, Rex Parker, Gaétan Mayer & Nabil G. Seidah. (2010) Effects of the Prosegment and pH on the Activity of PCSK9. Journal of Biological Chemistry 285:52, pages 40965-40978.
Crossref
Crossref
Greg Welder, Issam Zineh, Michael A. Pacanowski, Jason S. Troutt, Guoqing Cao & Robert J. Konrad. (2010) High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. Journal of Lipid Research 51:9, pages 2714-2721.
Crossref
Crossref
Jean Davignon, Geneviève Dubuc & Nabil G. Seidah. (2010) The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis. Current Atherosclerosis Reports 12:5, pages 308-315.
Crossref
Crossref
Bin Dong, Minhao Wu, Hai Li, Fredric B. Kraemer, Khosrow Adeli, Nabil G. Seidah, Sahng Wook Park & Jingwen Liu. (2010) Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. Journal of Lipid Research 51:6, pages 1486-1495.
Crossref
Crossref
Hai Li & Jingwen Liu. (2010) Identification of Heterogeneous Nuclear Ribonucleoprotein K as a Transactivator for Human Low Density Lipoprotein Receptor Gene Transcription. Journal of Biological Chemistry 285:23, pages 17789-17797.
Crossref
Crossref
Nidhi Gupta, Niels Fisker, Marie-Claude Asselin, Marie Lindholm, Christoph Rosenbohm, Henrik Ørum, Joacim Elmén, Nabil G. Seidah & Ellen Marie Straarup. (2010) A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo. PLoS ONE 5:5, pages e10682.
Crossref
Crossref
Zhigang Wang, Tong Yao & Zhenyuan Song. (2010) Chronic Alcohol Consumption Disrupted Cholesterol Homeostasis in Rats: Down‐Regulation of Low‐Density Lipoprotein Receptor and Enhancement of Cholesterol Biosynthesis Pathway in the Liver. Alcoholism: Clinical and Experimental Research 34:3, pages 471-478.
Crossref
Crossref
Hong Lan, Ling Pang, Marsha M. Smith, Diane Levitan, Wei Ding, Li Liu, Lixin Shan, Vidhi V. Shah, Maureen Laverty, Gladys Arreaza, Qing Zhang, Nicholas J. Murgolo, Marco Hernandez, Jonathan R. Greene, Eric L. Gustafson, Marvin L. Bayne, Harry R. Davis & Joseph A. Hedrick. (2010) Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells. Journal of Cellular Physiology, pages n/a-n/a.
Crossref
Crossref
Hai Li, Bin Dong, Sahng Wook Park, Hyun-Sook Lee, Wei Chen & Jingwen Liu. (2009) Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine. Journal of Biological Chemistry 284:42, pages 28885-28895.
Crossref
Crossref
Steve Poirier, Gaetan Mayer, Viviane Poupon, Peter S. McPherson, Roxane Desjardins, Kevin Ly, Marie-Claude Asselin, Robert Day, Franck J. Duclos, Mark Witmer, Rex Parker, Annik Prat & Nabil G. Seidah. (2009) Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation. Journal of Biological Chemistry 284:42, pages 28856-28864.
Crossref
Crossref